Millennium Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,085,705
| Closed | -$26.2M | – | 7103 |
|
|
2023
Q1 | $26.2M | Buy |
1,085,705
+662,410
| +156% | +$8.31M | 0.02% | 1145 |
|
|
2022
Q4 | $4.47M | Buy |
+423,295
| New | +$3.42M | ﹤0.01% | 2911 |
|
|
2022
Q3 | – | Sell |
-42,540
| Closed | -$170K | – | 7702 |
|
|
2022
Q2 | $170K | Buy |
+42,540
| New | +$202K | ﹤0.01% | 5715 |
|
|
2022
Q1 | – | Sell |
-546,202
| Closed | -$3.07M | – | 7837 |
|
|
2021
Q4 | $3.07M | Sell |
546,202
-237,320
| -30% | -$1.51M | ﹤0.01% | 3361 |
|
|
2021
Q3 | $5.01M | Buy |
783,522
+219,834
| +39% | +$1.41M | ﹤0.01% | 2855 |
|
|
2021
Q2 | $4.75M | Buy |
563,688
+227,727
| +68% | +$1.84M | ﹤0.01% | 2826 |
|
|
2021
Q1 | $3.53M | Buy |
335,961
+187,153
| +126% | +$2.63M | ﹤0.01% | 2967 |
|
|
2020
Q4 | $2.52M | Sell |
148,808
-7,512
| -5% | -$113K | ﹤0.01% | 3051 |
|
|
2020
Q3 | $2.01K | Sell |
156,320
-464,750
| -75% | -$5.87M | ﹤0.01% | 2592 |
|
|
2020
Q2 | $8.76M | Buy |
621,070
+41,204
| +7% | +$520K | 0.01% | 1307 |
|
|
2020
Q1 | $5.33M | Buy |
579,866
+542,553
| +1,454% | +$6.99M | 0.01% | 1296 |
|
|
2019
Q4 | $556K | Buy |
37,313
+15,989
| +75% | +$142K | ﹤0.01% | 3319 |
|
|
2019
Q3 | $145K | Buy |
+21,324
| New | +$216K | ﹤0.01% | 3883 |
|
Other funds holding PRVB
Millennium Management's PRVB Position: Q2 2023 in Review
Millennium Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,085,705 shares — an estimated $26.2M sold.
Millennium Management first reported a position in PRVB in Q3 2019 and held it in 13 quarters. The position peaked at $26.2M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Millennium Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Millennium Management sold 1,085,705 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $26.2M.
- Millennium Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
- Millennium Management's Provention Bio, Inc. Common Stock position peaked at $26.2M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.